Overview:
OncoPro Homologous Recombination Deficiency Assay (OncoPro HRD Assay) TestIntroduction: The OncoPro Homologous Recombination Deficiency Assay (OncoPro HRD Assay) Test is a diagnostic tool designed to detect BRCA1, BRCA2, and ATM mutations in tissue preserved in formalin-fixed paraffin-embedded (FFPE) blocks, facilitating the guidance of cancer therapy. Associated with breast, ovarian, or prostate cancer, these oncologic conditions present with abnormal growths, pain, and severe complications like metastasis if untreated, particularly in individuals with genetic predisposition or family history. Per the 2023 National Comprehensive Cancer Network guidelines, the test employs molecular pathology with PCR technology, delivering detailed genetic identification over 5-7 days with high sensitivity and specificity, making it a valuable tool for therapeutic decision-making in molecular pathology settings. This diagnostic falls under cancer screening and targets individuals with systemic or reproductive symptoms, addressing the challenge of accurate mutation classification to guide PARP inhibitor therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its tissue-based approach ensures reliable detection.
Other Names: HRD Assay Test.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: Introduced in the 2010s by various molecular labs, this test advanced cancer therapy by standardizing HRD detection.
Purpose: The test detects BRCA1 mutations, BRCA2 mutations, and ATM mutations to guide cancer therapy, assess oncologic status, and inform treatment and prevention strategies.
Test Parameters: Presence of BRCA1 mutations, BRCA2 mutations, and ATM mutations, detected with high specificity to indicate therapeutic relevance, typically observable in tissue at altered genetic patterns during active disease, with mutation prevalence and type assessed to determine severity and distribution, providing a comprehensive profile of tumor damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected genetic components.
Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report abnormal growths, pain, or recent cancer treatment.
Specimen: Tissue 0.5-2 cma³, collected as FFPE, transported indefinitely to maintain sample viability.
Sample Stability at Room Temperature: Indefinite with proper paraffin embedding to preserve tissue integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: Not refrigerated, as FFPE blocks are stable at room temperature with proper storage.
Sample Stability at Frozen: Not recommended, as freezing may disrupt tissue structure, increasing the risk of false negatives and compromising diagnostic accuracy.
Medical History: Patients should provide details on abnormal growths, pain, prior cancer, or family history of oncologic disease, as well as any recent trauma or treatments.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated cancer including metastasis, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves tissue processing, DNA extraction, PCR amplification, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 5-7 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays in processing, improper fixation, cross-contamination with other samples, or recent therapy can affect results. Correlation with imaging or clinical evaluation is recommended to confirm findings.
Clinical Significance: A positive result indicates possible HRD, necessitating further investigation like imaging or oncology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.
Specialist Consultation: Oncologists or geneticists should be consulted for case management, treatment planning, and coordination with cancer programs.
Additional Supporting Tests: BRCA testing, biopsy review, or genetic counseling for confirmation.
Test Limitations: The test may produce false negatives in low tumor burden or false positives in variants of uncertain significance, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: NCCN Guidelines 2023, Journal of Molecular Diagnostics 2024, Molecular Pathology 2025.
